| abstract |
The invention relates to a DGAT inhibitor of formula (I): including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —C(═O)—; —O—C(═O)—; C(═O)—C(═O)—; —NR x —C(═O)—; —Z 1 —C(O)—; —Z 1 —NR x —C(═O)—; —C(═O)—Z 1 —; —NR x —C(═O)—Z 1 —; —S(═O)p-; —C(═S)—; —NR x —C(═S)—; —Z 1 —C(═S)—; —Z 1 —NR x —C(═S)—; —C(═S)—Z1-; —NR x —C(═S)—Z—; Y represents NR x —C(=0)-Z 2 —; —NR x —C(=0)-Z 2 —NR y —; —NR x —C(=0)-Z 2 —NR y —C(=0)-; —NR x —C(=0)-Z 2 —NR y —C(=0)-O—; —NR x —C(=0)-Z 2 -0-; —NR x —C(=0)-Z 2 -0-C(=0)-; —NR x —C(=0)-Z 2 —C(=0)-; —NR x —C(=0)-Z 2 —C(=0)-; —NR x —C(=0)-0-Z 2 —C(=0)-; —NR x —C(=0)-0-Z 2 —C(=0)-0-; —NR x —C(═O)—O—Z 2 —O—C(═O)—; —NR x —C(═O)—Z 2 —C(═O)—NR y —; —NR x —C(═O)—Z 2 —NR y —C(=0)-NR y —; —C(═O)—Z 2 —; —C(═O)—Z 2 —O—; —C(=0)-NR x —Z 2 —; —C(=0)-NR x —Z 2 -0-; —C(=0)-NR x —Z 2 —C(=0)-0-; —C(=0)-NR x —Z 2 -0-C(=0)-; —C(=0)-NR x —Z 2 —NR y —; —C(=0)-NR x —Z 2 —NR y —C(=0)-; —C(=0)-NR x —Z 2 —NR y —C(=0)-0-; R 1 represents C 1-12 alkyl optionally substituted with cyano, C 1-4 alkyloxy, C 1-4 alkyl-oxyC 1-4 alkyloxy, C 3-6 Cycloalkyl or aryl; C 2-6 alkenyl; C 2-6 alkynyl; C 3-6 cycloalkyl; adamantanyl; aryl 1 ; aryl 1 C 1-6 alkyl; Het 1 ; or Het 1 C 1-6 alkyl; provided that when Y represents —NR X —C(═O)—Z 2 —; —NR x —C(=0)-Z 2 —NR y ; —NR X —C(═O)—Z 2 —C(═O)—NR y —; —C(═O)—Z 2 —; —NR x —C(=0)-Z 2 —NR y —C(=0)-NR y —; —C(═O)—NR X —Z 2 —; —C(═O)—NR X —O—Z 2 —; or —C(=0)-NR x —Z 2 —NR y —; then R 1 may also represent hydrogen; R 2 represents hydrogen, C 1-12 alkyl, C 2-6 alkenyl or R 3 ; provided that if X represents —O—C(═O)—; the R 2 represents R 3 ; and provided that (A) is excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds. |